Akram Ghahghaei-Nezamabadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akram Ghahghaei-Nezamabadi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Afsaneh Tehranian
Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Akram Seifollahi
Department of Pathology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Amin Nakhostin-Ansari
Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Faezeh Aghajani
Fetal Care and Surgery Center, Division of Maternal-Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
1 shared publication - Neda Zarei
Department of Obstetrics and Gynecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Sara Kasraei
Department of Obstetrics and Gynecology, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 1 March 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (3) , 857-863
Comparison of cytopathologic findings in patients with negative Pap test and positive high-risk HPV infection among three groups
Purpose Comparison of colposcopy-guided biopsy and endocervical cytologic (ECC) results in patients with negative Papanicolaou (Pap) and positive high-risk (HR) HPV tests in the three groups of HPV 16/18, non-16/18 HR-HPV (other HR-HPV), and concurrent infection of either HPV 16/18 and at least one subtype of other HR-HPVs. Methods This cross-sectional study was conducted among women aged 30–65 who had negative Pap and positive HR-HPV DNA tests. Pap test was performed using liquid cytology. For HPV DNA testing, the polymerase chain reaction (PCR) method was used. Results Among 394 participants, 111 (28.2%) were in the HPV 16/18, 226 (57.4%) in the Other HR-HPV, and 57 (14.4%) in the concurrent group. The mean age of participants was 35.71 ± 7.1 years. Cervical intraepithelial neoplasia (CIN) grade 2/3 were seen in 29 (26.1%) patients of HPV 16/18, 60 (26.5%) of other HR-HPV, and 18 (31.6%) of concurrent infection group (P = 0.593). HPV 52 was the most common subtype in the other HR-HPV group (15%). Conclusions The risk of high-grade CIN lesions in patients with negative Pap test and positive other HR-HPV was not significantly less than patients with positive HPV 16/18. Besides, the risk of losing the patients to 1-year follow-up seems high.
- 1 March 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (3) , 857-863
Comparison of cytopathologic findings in patients with negative Pap test and positive high-risk HPV infection among three groups
Purpose Comparison of colposcopy-guided biopsy and endocervical cytologic (ECC) results in patients with negative Papanicolaou (Pap) and positive high-risk (HR) HPV tests in the three groups of HPV 16/18, non-16/18 HR-HPV (other HR-HPV), and concurrent infection of either HPV 16/18 and at least one subtype of other HR-HPVs. Methods This cross-sectional study was conducted among women aged 30–65 who had negative Pap and positive HR-HPV DNA tests. Pap test was performed using liquid cytology. For HPV DNA testing, the polymerase chain reaction (PCR) method was used. Results Among 394 participants, 111 (28.2%) were in the HPV 16/18, 226 (57.4%) in the Other HR-HPV, and 57 (14.4%) in the concurrent group. The mean age of participants was 35.71 ± 7.1 years. Cervical intraepithelial neoplasia (CIN) grade 2/3 were seen in 29 (26.1%) patients of HPV 16/18, 60 (26.5%) of other HR-HPV, and 18 (31.6%) of concurrent infection group (P = 0.593). HPV 52 was the most common subtype in the other HR-HPV group (15%). Conclusions The risk of high-grade CIN lesions in patients with negative Pap test and positive other HR-HPV was not significantly less than patients with positive HPV 16/18. Besides, the risk of losing the patients to 1-year follow-up seems high.